MPR

Roflumilast Cream Has Long-Term Safety, Efficacy in Young Children

HealthDay News — For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile and efficacy for up to 56 weeks, according to a study ...
Healio

Zoryve cream 0.15% improves atopic dermatitis across diverse skin types

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...
Healio

Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. AD affected more than 35% body surface area of study ...

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in ...

ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages ...
Monthly Prescribing Reference

Zoryve Cream 0.15% for Atopic Dermatitis Now Available

Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...
Seeking Alpha

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...
Business Wire

Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic ...

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, ...
Nasdaq

Arcutis Biotherapeutics Presents Positive Data on ZORYVE® Cream and Foam for Atopic Dermatitis and Psoriasis at 2025 AAD Annual Meeting

Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional treatments ...
Seeking Alpha

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well tolerated Once-daily, steroid-free cream can be used anywhere ...
Yahoo Finance

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down ...

Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as ...
Nasdaq

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in ...